Tesamorelin peptide stacks: what the evidence actually supports

Last updated 2026-07-24

What is a "tesamorelin peptide stack" and where does the idea come from?

A "stack" just means combining two or more peptides on the theory that they work through different mechanisms and add up to more than either alone. The most common pairing discussed online is tesamorelin plus IGF-1 LR3, sometimes with a GHRP (a ghrelin-mimetic secretagogue) thrown in too. The logic sounds coherent: tesamorelin is a growth hormone releasing hormone (GHRH) analogue that pushes the pituitary to release more of the body's own GH, while IGF-1 LR3 is a long-acting engineered version of the downstream hormone that GH itself triggers the liver to produce. Stack them, the theory goes, and you're hitting the axis at two points instead of one. That reasoning isn't crazy on paper. It's also not tested. Tesamorelin's approval and every phase 3 trial behind it evaluated the drug alone, not in combination with IGF-1 LR3 or any other injectable peptide ^{[1] [2]}. IGF-1 LR3 itself has never gone through FDA review for human use; it's a lab research compound, not a medicine with an approved label, dosing chart, or safety monitoring protocol. So the honest starting point is this: the stack is a popular idea in enthusiast and bodybuilding circles, not a studied clinical protocol. If you came here looking for a dosing schedule for the combination, there isn't a reliable one to give you, because nobody has published the pharmacokinetics of tesamorelin and IGF-1 LR3 given together.

Is tesamorelin actually FDA-approved, and for what?

Yes. Tesamorelin, sold under the brand name Egrifta (and later Egrifta SV), is FDA-approved for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy ^{[1] [3]}. That's the entire approved indication. It is not approved for general fat loss, for anti-aging use, for athletic performance, or for GH support in people without HIV-associated lipodystrophy. The approval rests on pooled phase 3 data from two multicenter, double-blind, placebo-controlled trials plus safety extension data, published in the Journal of Clinical Endocrinology and Metabolism ^[4]. Tesamorelin is a synthetic analogue of human GHRH, engineered for a longer half-life than native GHRH, and it works by stimulating the pituitary's own GH-releasing machinery rather than delivering GH directly ^{[3] [2]}. A 2011 review in Nature Reviews Drug Discovery covers its development path and mechanism in more detail ^[2]. Everything below the phase 3 data (LR3 stacking, cycling protocols, combining with GHRPs) is off-label extrapolation. It may or may not be reasonable in a given clinical judgment, but it isn't what the drug's approval or trial evidence covers, and it's worth being clear-eyed about that distinction before anyone spends money or takes on risk.

What does the phase 3 trial evidence actually show for tesamorelin alone?

The pooled phase 3 analysis, published in 2010, is the backbone of the approval ^[4]. It combined two multicenter, double-blind, placebo-controlled trials in HIV-positive patients with excess abdominal fat, dosed at 2 mg subcutaneously once daily, with safety extension follow-up. The trials measured visceral adipose tissue (VAT) by CT scan as the primary endpoint, and reported reductions in VAT alongside improvements in triglycerides, and no worsening of glucose parameters, over the study period ^[4]. Follow-on analyses have dug into more specific outcomes. A study in AIDS (2017) found that visceral fat reduction with tesamorelin correlated with improved liver enzymes in HIV patients ^[5]. A 2019 randomized, double-blind, multicenter trial in The Lancet HIV looked specifically at non-alcoholic fatty liver disease (NAFLD) in HIV patients and found effects on hepatic fat with tesamorelin treatment ^[6]. Mechanistic work has gone even further: a JCI Insight paper examined hepatic transcriptomic signatures in HIV-associated NAFLD after tesamorelin ^[7], and a Scientific Reports paper mapped proteomic and transcriptomic response pathways ^[8], both trying to explain why fat quality, more than fat quantity, seems to shift with treatment. A 2021 AIDS paper reported that tesamorelin improves fat quality independent of changes in fat quantity, a distinction that matters for anyone assuming "less fat" and "healthier fat" are the same thing ^[9]. More recent work keeps testing tesamorelin in updated contexts. A 2024 AIDS study assessed efficacy and safety of tesamorelin specifically in people with HIV on integrase inhibitors, a now-common antiretroviral class ^[10]. A 2025 Journal of Infectious Diseases study looked at tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity ^[11]. A 2026 meta-analysis of randomized controlled trials in Obesity Research & Clinical Practice pooled body composition, hepatic fat, metabolic, and safety outcomes across the RCT evidence base ^[12]. None of this trial program, old or new, includes IGF-1 LR3 or peptide stacking as a study arm.

What does the evidence say about combining tesamorelin with IGF-1 LR3?

Nothing, directly. There is no published randomized trial, no pharmacokinetic study, and no FDA safety review of tesamorelin combined with IGF-1 LR3. The population pharmacokinetic analysis of tesamorelin, published in Clinical Pharmacokinetics in 2015, characterized the drug's behavior in HIV-infected patients and healthy subjects as a standalone agent, not in combination with other peptides ^[13]. That absence of data cuts both ways. It doesn't prove the combination is dangerous. It also doesn't provide any basis to claim it's safe, effective, or dosed correctly at any particular ratio. IGF-1 LR3 itself carries known theoretical risks around hypoglycemia (it has strong insulin-like activity) and, because it drives cell proliferation signaling, long-term safety concerns that have never been studied in trials of the length or rigor that support tesamorelin's approval. Stacking an approved, well-characterized GHRH analogue with an unapproved, unregulated IGF-1 analogue means the known safety profile of one drug gets combined with the largely unknown profile of another, and nobody has published data on what that combination actually does in humans. If you're weighing best peptide to stack with tesamorelin, the honest framing is: some combinations (like tesamorelin plus a GH secretagogue) have more mechanistic plausibility discussed in review literature, but even those pairings lack dedicated combination trials. IGF-1 LR3 sits further out on that spectrum because it isn't an FDA-approved substance at all.

How is tesamorelin dosed in the trials that support its approval?

The phase 3 program used 2 mg of tesamorelin, given as a once-daily subcutaneous injection, in adults with HIV-associated lipodystrophy ^[4]. That's the dose tied to the approved label and the outcome data on visceral fat, triglycerides, and liver-related measures. It is not a dose validated for people without HIV-associated lipodystrophy, and it is not a dose studied in combination with any other injectable peptide. A post hoc analysis published in the Journal of Clinical Translational Science looked at whether the presence or absence of dorsocervical fat (sometimes called a "buffalo hump") changed how patients responded to tesamorelin in the original phase 3 trial, which gives some texture to how individual variation showed up within the approved dosing regimen ^[14]. For practical injection mechanics, including where and how the dose gets administered, see tesamorelin how to inject and tesamorelin injection sites. Storage matters too, since GHRH analogues are temperature-sensitive peptides; see does tesamorelin need to be refrigerated.

What side effects and safety signals show up with tesamorelin?

The known side effect profile comes from the same phase 3 and extension trial data behind the approval. Injection site reactions (redness, itching, swelling) are common, given it's a daily subcutaneous injection. Joint pain, myalgia, and peripheral edema have been reported, consistent with what's seen with other agents that raise GH and IGF-1 levels ^{[3] [15]}. Because tesamorelin raises IGF-1, it carries a class-level caution around glucose metabolism; the trials tracked glucose parameters closely and reported no clinically meaningful worsening in the approved population, but this is monitored, not ignored ^[4]. A 2011 AIDS study looked specifically at inflammatory markers in HIV patients with excess abdominal fat and their relationship to visceral fat reduction with tesamorelin, adding another layer to the safety and mechanism picture beyond the primary endpoints ^[16]. Review articles in Drugs (2011) ^[15] and The Annals of Pharmacotherapy (2012) ^[3] both summarize the safety and efficacy data specifically in the context of HIV-associated lipodystrophy, which remains the only population with this depth of evidence. None of this safety data was collected in people also taking IGF-1 LR3. If you add an unstudied peptide on top of tesamorelin, you're more than adding its own risks, you're also losing the ability to attribute any side effect that shows up to one substance or the other.

Does tesamorelin work for women, or only the men studied in HIV trials?

The core phase 3 trials enrolled HIV-positive adults with lipodystrophy, and the population was predominantly male, which is a real limitation worth naming directly rather than glossing over. Sex-specific efficacy and dosing nuances are addressed in more depth at can women take tesamorelin peptide, but the short version is that the approved indication doesn't exclude women, and lipodystrophy affects both sexes, though trial representation and some pharmacokinetic questions differ. Broader reviews of lipodystrophy diagnosis and management, including a 2022 Journal of Clinical Endocrinology and Metabolism paper on the approach to patients with lipodystrophy ^[17] and a 2012 Annales d'Endocrinologie paper on diagnosing lipodystrophy syndromes ^[18], give useful context on how heterogeneous this condition is across sex, HIV status, and underlying cause, which matters because tesamorelin's approval is narrowly tied to one specific etiology (HIV-associated) rather than lipodystrophy broadly.

How does off-label or non-HIV use of tesamorelin compare to the approved population?

People without HIV, seeking visceral fat reduction or general GH support, are using tesamorelin entirely off-label. That's legal for a physician to prescribe (off-label prescribing is a normal part of medical practice), but it means the visceral fat, liver fat, and triglyceride data from the phase 3 trials, all collected in HIV-positive patients with lipodystrophy, may not translate directly to a metabolically different population. Nobody has run an equivalent phase 3 program in HIV-negative adults seeking visceral fat reduction for its own sake. The table below lays out what's actually established versus what's assumed. | Question | HIV-associated lipodystrophy (approved use) | Off-label / general population use |

How does tesamorelin compare to other GH-axis peptides people stack it with?

Broader peptide literature gives some context for where tesamorelin sits relative to other agents floating around the same GH-axis conversation. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics generally, including applications and open challenges across the peptide category ^[19]. A companion 2026 primer in The American Journal of Sports Medicine walks orthopaedic and sports medicine physicians through injectable peptide therapy as a category ^[20]. A 2026 Sports Medicine paper specifically reviews safety and efficacy data for approved versus unapproved peptide therapies used for musculoskeletal injuries and athletic performance, which is directly relevant background for anyone treating tesamorelin as one ingredient in a broader performance stack ^[21]. A 2026 International Journal of Molecular Sciences review covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions more broadly, again as category-level background rather than tesamorelin-specific combination data ^[22]. The consistent theme across this literature: approved peptides like tesamorelin have a real evidence base tied to a specific population and endpoint, while most of what circulates as "stacks" in enthusiast use sits in the unapproved, unstudied category, IGF-1 LR3 included.

How is a compounded or unapproved peptide like IGF-1 LR3 regulated differently from tesamorelin?

This distinction matters more than most people realize. Tesamorelin, as Egrifta/Egrifta SV, went through the FDA's full new drug approval pathway, meaning it has an approved label, manufacturing standards, and a defined indication verified in Drugs@FDA ^[23]. IGF-1 LR3 has no FDA approval for human use at all. Separately, U.S. law does allow licensed pharmacies to compound certain drugs under specific bulk substance lists. The FDA maintains lists of bulk drug substances that can be used in compounding under Section 503A (21 CFR 216.23) ^[24] and under Section 503B for outsourcing facilities (21 CFR 216.24) ^[25], governed by the compounding statute at 21 U.S.C. 353a ^[26]. The FDA's own bulk drug substances page for 503A explains the framework directly: it describes the substances FDA has evaluated for inclusion on these lists and the criteria used ^[27], and the agency separately maintains a running list of bulk substances nominated for compounding consideration ^[28]. IGF-1 LR3's regulatory status under these bulk substance lists is a materially different question from tesamorelin's FDA-approved drug status, and conflating "a pharmacy can compound this" with "this is FDA-approved for this use" is a common and important error. Separately, testing labs have gotten better at catching unapproved GHRH analogues and secretagogues in anti-doping and forensic contexts; a 2021 paper in Drug Testing and Analysis covers advances in detecting synthetic GHRH analogues ^[29], a reminder that this category is monitored in competitive sport, not a gray area athletes should assume flies under the radar.

What would a provider-reviewed approach to tesamorelin actually look like?

Given all of the above, the responsible path is narrower than the online stacking discourse suggests. Tesamorelin has real phase 3 evidence for one job: reducing visceral abdominal fat in HIV-associated lipodystrophy, at 2 mg/day subcutaneous ^[4]. Used off-label outside that population, it's a reasonable clinical decision in some cases, made with a prescriber who understands the limits of the data, but it stops being an evidence-based decision the moment IGF-1 LR3 or another unapproved peptide gets added to the syringe with no combination data behind it. Tesamorelin Co's role here is to point toward the provider-reviewed route rather than a self-sourced one: getting tesamorelin through a licensed prescriber and a legitimate, pharmacy-fulfilled channel, rather than from an unregulated research-chemical seller, is the difference between taking an FDA-approved drug at a studied dose and taking an unknown-purity substance at a guessed one. That's true whether you're using tesamorelin alone or considering it as part of a broader regimen; the stacking decision should sit with a prescriber weighing your actual labs and history, not a forum thread. If cost is the barrier to going the provider-reviewed route, it's worth understanding the real numbers before assuming a research-chemical source is the only affordable option; see tesamorelin cost for that breakdown.

Frequently asked questions

What is a tesamorelin peptide stack?

It's the practice of combining tesamorelin with one or more other peptides, most commonly IGF-1 LR3, sometimes a GHRP, based on the idea that hitting the GH axis at multiple points adds benefit. No phase 3 trial or FDA review has evaluated tesamorelin in combination with any other peptide; the approval and all supporting trial data cover tesamorelin alone ^[3][5].

Is the tesamorelin and IGF-1 LR3 stack backed by any clinical trials?

No. There is no published randomized trial evaluating tesamorelin combined with IGF-1 LR3. Tesamorelin's phase 3 program, the basis for FDA approval, tested the drug alone in HIV-associated lipodystrophy ^[5]. IGF-1 LR3 has no FDA approval for human use and no controlled trial data of its own, let alone in combination.

Is tesamorelin FDA-approved for visceral fat loss generally, or just for HIV patients?

Tesamorelin (Egrifta/Egrifta SV) is FDA-approved specifically for reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy ^[3][4]. It is not approved for visceral fat reduction in people without HIV-associated lipodystrophy; that use is off-label, even though the underlying mechanism (raising GH and IGF-1 via GHRH stimulation) is the same in anyone.

What dose of tesamorelin was used in the trials behind its approval?

The pooled phase 3 trials used 2 mg of tesamorelin injected subcutaneously once daily in HIV-positive adults with excess abdominal fat, with safety extension follow-up beyond the initial trial period ^[5]. This is the only dose with this depth of controlled trial support; doses used in off-label or stacked protocols are not validated by this data.

Can women take tesamorelin, or is it only proven in men?

The core phase 3 trials skewed heavily male, since the HIV-associated lipodystrophy population studied was predominantly men. Tesamorelin isn't restricted to men by its approval, and lipodystrophy affects women too, but trial representation is a real limitation. See can women take tesamorelin peptide for a fuller breakdown.

What are the known side effects of tesamorelin from the approval trials?

Reported effects from the phase 3 and extension data include injection site reactions, joint pain (arthralgia), myalgia, and peripheral edema, consistent with raising GH/IGF-1 levels ^[4][16][18]. Glucose parameters were monitored closely in trials; the approved population didn't show clinically meaningful worsening, but it remains a tracked risk given IGF-1's role in glucose metabolism ^[5].

Does tesamorelin help with liver fat or NAFLD in addition to visceral fat?

Yes, in the HIV-positive population studied. A 2019 randomized, double-blind, multicenter trial in The Lancet HIV found effects on hepatic fat with tesamorelin ^[7], and a 2017 AIDS study linked visceral fat reduction to improved liver enzymes ^[6]. Mechanistic studies have mapped hepatic transcriptomic and proteomic changes associated with treatment ^[8][9].

Is IGF-1 LR3 FDA-approved or legal to buy for personal use?

IGF-1 LR3 is not FDA-approved for any human use. It circulates as a research chemical, outside the FDA-approved drug pathway that tesamorelin went through. Separately, FDA maintains lists of bulk substances eligible for pharmacy compounding under 21 CFR 216.23 and 216.24 ^[26][27], a distinct legal question from whether a substance is an approved drug.

What's the best peptide to stack with tesamorelin, if any?

There's no combination with dedicated trial data behind it. Some pairings (like tesamorelin with a GH secretagogue) have more mechanistic plausibility discussed in peptide review literature ^[21][22][23] than others, but none have phase 3-level evidence. See best peptide to stack with tesamorelin for a fuller comparison of what's actually claimed versus proven.

How is tesamorelin injected, and does it need refrigeration?

Tesamorelin in the approved trials was given as a daily subcutaneous injection ^[5]. Storage and reconstitution are temperature-sensitive; see tesamorelin how to inject, tesamorelin injection sites, and does tesamorelin need to be refrigerated for the practical specifics.

Does tesamorelin affect cognition or brain health in people with HIV?

A 2025 study in The Journal of Infectious Diseases specifically examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity ^[12]. This is a narrower, more recent research thread within the HIV population and shouldn't be generalized to cognitive claims outside that studied group.

How much does tesamorelin cost, and does insurance cover off-label or stacked use?

Cost varies significantly by pharmacy channel and whether insurance covers the approved indication. Insurance coverage generally tracks the FDA-approved use (HIV-associated lipodystrophy); off-label use, and any add-on peptides like IGF-1 LR3, are typically out-of-pocket. See tesamorelin cost for a detailed breakdown.

Sources

1. PubMed, Tesamorelin overview, PMID 31644039: Tesamorelin's clinical development and approval evidence covers the drug as a single agent, not in combination with other peptides.
2. Nature Reviews Drug Discovery, Tesamorelin, PMID 21283099: Tesamorelin is a synthetic GHRH analogue engineered for a longer half-life than native GHRH, working by stimulating pituitary GH release.
3. Annals of Pharmacotherapy, Tesamorelin review, PMID 22298602: Tesamorelin is a growth hormone-releasing factor analogue used for HIV-associated lipodystrophy, with a defined side effect profile including injection site reactions and joint pain.
4. Journal of Clinical Endocrinology and Metabolism, pooled phase 3 tesamorelin trials, PMID 20554713: Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials of tesamorelin 2 mg/day subcutaneous in HIV patients with excess abdominal fat, plus safety extension data, forms the basis of FDA approval.
5. AIDS, visceral fat and liver enzymes, PMID 28832410: Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV patients.
6. The Lancet HIV, tesamorelin and NAFLD RCT, PMID 31611038: A randomized, double-blind, multicenter trial found effects of tesamorelin on non-alcoholic fatty liver disease in HIV-positive patients.
7. JCI Insight, hepatic transcriptomic signatures, PMID 32701508: Tesamorelin affects hepatic transcriptomic signatures in HIV-associated NAFLD.
8. Scientific Reports, tesamorelin response pathways, PMID 34006921: Targeted proteomic and transcriptomic analysis has mapped tesamorelin response pathways in HIV-associated NAFLD.
9. AIDS, fat quality vs fat quantity, PMID 33756511: Tesamorelin improves fat quality independent of changes in fat quantity.
10. AIDS, tesamorelin with integrase inhibitors, PMID 38905488: A 2024 study assessed the efficacy and safety of tesamorelin specifically in people with HIV taking integrase inhibitors.
11. Journal of Infectious Diseases, tesamorelin and neurocognition, PMID 39813152: A 2025 study examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity.
12. Obesity Research & Clinical Practice, tesamorelin meta-analysis, PMID 41545261: A 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy.
13. Clinical Pharmacokinetics, population PK analysis, PMID 25358450: A population pharmacokinetic analysis characterized tesamorelin behavior in HIV-infected patients and healthy subjects as a standalone agent.
14. Journal of Clinical and Translational Science, dorsocervical fat post hoc analysis, PMID 36845310: A post hoc analysis of the phase 3 trial examined whether presence of dorsocervical fat changed tesamorelin response.
15. Drugs, tesamorelin review, PMID 21668043: Review of tesamorelin's use and safety profile in the management of HIV-associated lipodystrophy.
16. AIDS, tesamorelin and inflammatory markers, PMID 21516030: Tesamorelin's effects on inflammatory markers in HIV patients relate to the degree of visceral adipose reduction.
17. Journal of Clinical Endocrinology and Metabolism, approach to lipodystrophy, PMID 35137140: Clinical approach to diagnosing and managing patients with lipodystrophy covers the heterogeneity of the condition across causes and sexes.
18. Annales d'Endocrinologie, diagnosing lipodystrophy syndrome, PMID 22748602: Lipodystrophy syndromes are diagnostically heterogeneous, varying by underlying cause rather than a single uniform presentation.
19. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, therapeutic peptides in orthopaedics, PMID 41490200: A 2026 review covers therapeutic peptides in orthopaedics, including applications and open challenges across the peptide category.
20. American Journal of Sports Medicine, injectable peptide therapy primer, PMID 41476424: A 2026 primer reviews injectable peptide therapy as a category for orthopaedic and sports medicine physicians.
21. Sports Medicine, approved vs unapproved peptide therapies, PMID 41966639: A 2026 review compares safety and efficacy data for approved versus unapproved peptide therapies used for musculoskeletal injury and athletic performance.
22. International Journal of Molecular Sciences, therapeutic peptides review, PMID 42123471: A 2026 review covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions as a category.
23. Drugs@FDA, FDA-approved drug products database: Tesamorelin (Egrifta/Egrifta SV) is listed as an FDA-approved drug product with a defined indication.
24. eCFR, 21 CFR 216.23, the 503A Bulks List: FDA maintains a list of bulk drug substances that can be used in compounding under Section 503A, a distinct regulatory track from FDA drug approval.
25. eCFR, 21 CFR 216.24, the 503B Bulks List: FDA maintains a separate bulk drug substances list for outsourcing facilities compounding under Section 503B.
26. Cornell Law School, 21 U.S.C. 353a, pharmacy compounding: Federal law under 21 U.S.C. 353a governs the conditions under which pharmacy compounding is permitted.
27. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA explains the framework and criteria it uses to evaluate bulk drug substances for inclusion on the 503A compounding list.
28. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): FDA maintains a running list of bulk drug substances nominated for consideration for compounding use.
29. Drug Testing and Analysis, detection of GHRH synthetic analogs, PMID 34665524: Advances in analytical testing have improved detection of synthetic GHRH analogues in anti-doping and forensic contexts.